ALK and non-small cell lung carcinoma: Recently, two clinical phase III studies (global study: ALEX [189,190] and in Japan: J-ALEX [191]) were performed to compare alectinib and crizotinib as the first-line treatment of patients with ALK-positive NSCLC who had not received prior systemic therapy for metastatic disease.